Proton shares: performance forecast for the first three quarters of 2025
Stock code: 300363 Stock abbreviation: Proton Shares Announcement number: 2025-052
Chongqing Porton Pharmaceutical Technology Co., Ltd.
Performance forecast for the first three quarters of 2025
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
1. Performance forecast for this period
(1) Performance forecast period
January 1, 2025 to September 30, 2025.
(2) Performance forecast: turning losses into profits
Items This reporting period Net profit attributable to shareholders of listed companies in the same period last year Profit: RMB 73.2 million to RMB 88.2 million Loss: RMB 206.43 million attributable to shareholders of listed companies, excluding non-
Profit: RMB 50 million ~ RMB 65 million Loss: Net profit from recurring gains and losses of RMB 213.5 million
In the first three quarters of 2025, the impact of the company's non-recurring gains and losses on net profit will be approximately 23.2 million yuan, and in the first three quarters of 2024, it will be approximately 7.07 million yuan.
2. Communication with the accounting firm
The relevant financial data in this performance forecast have not been audited by an accounting firm.
3. Explanation of reasons for performance changes
In the first three quarters of 2025, with the continuous enrichment and expansion of the company's customer pipeline and product pipeline, and the continuous improvement of R&D technical capabilities and product delivery capabilities, the company's overall business for the domestic and international markets has achieved steady growth. The company is expected to achieve operating income of 2.48 billion to 2.58 billion yuan, a year-on-year increase of 17% to 21%. Benefiting from the growth of the company's operating income, the scale effect has emerged, and the company's profitability has improved restoratively. In addition, the company continues to implement measures to reduce costs, increase efficiency and lean operations, improve operating efficiency, and the company's overall gross profit margin continues to improve year-on-year.
4. Other related instructions
This performance forecast is based on preliminary calculations by the company's finance department and has not been audited by a certified public accountant. The specific financial data will be disclosed in detail in the company's 2025 third quarter report. Investors are advised to make prudent decisions and pay attention to investment risks.
5. Documents for reference
(1) Explanation of the board of directors’ performance forecast for this period.
Announcement is hereby made.
Board of Directors of Chongqing Porton Pharmaceutical Technology Co., Ltd.
October 13, 2025